NCT03573544 - This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

April 7, 2022

Study Completion Date

April 7, 2022

Conditions

Metastatic Solid TumorsLocally Advanced Solid Tumors

Interventions

DRUG

OBI-888

For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.

DRUG

OBI-888

For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.

DEVICE

Globo H IHC Assay

This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.

Trial Locations (9)

National Cheng Kung University Hospital, Tainan City

Taipei Veterans General Hospital, Taipei

West Cancer Center and Research Institute, Germantown

China Medical University Hospital, Taichung

MD Anderson Cancer Center, Houston

USC/Norris Comprehensive Cancer Center, Los Angeles

Scripps Clinic Torrey Pines, La Jolla

Hoag Memorial Hospital Presbyterian, Newport Beach

Rutgers Cancer Institute of New Jersey, New Brunswick